Diversify Wealth Management LLC Increases Position in Edwards Lifesciences Co. (NYSE:EW)

Diversify Wealth Management LLC lifted its stake in Edwards Lifesciences Co. (NYSE:EW - Free Report) by 99.9% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 37,441 shares of the medical research company's stock after purchasing an additional 18,715 shares during the period. Diversify Wealth Management LLC's holdings in Edwards Lifesciences were worth $2,749,000 as of its most recent SEC filing.

A number of other large investors have also recently modified their holdings of EW. Wellington Management Group LLP lifted its holdings in Edwards Lifesciences by 86.3% in the third quarter. Wellington Management Group LLP now owns 31,532,725 shares of the medical research company's stock worth $2,080,845,000 after buying an additional 14,610,123 shares during the period. Assenagon Asset Management S.A. lifted its stake in shares of Edwards Lifesciences by 475.8% in the fourth quarter. Assenagon Asset Management S.A. now owns 4,243,976 shares of the medical research company's stock worth $314,182,000 after buying an additional 3,506,886 shares in the last quarter. Jacobs Levy Equity Management Inc. boosted its stake in Edwards Lifesciences by 239.9% during the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 3,693,663 shares of the medical research company's stock valued at $243,745,000 after purchasing an additional 2,606,950 shares during the last quarter. Nordea Investment Management AB boosted its position in shares of Edwards Lifesciences by 34.6% during the fourth quarter. Nordea Investment Management AB now owns 4,057,013 shares of the medical research company's stock valued at $301,355,000 after buying an additional 1,043,484 shares during the last quarter. Finally, Fisher Asset Management LLC boosted its holdings in shares of Edwards Lifesciences by 9.8% during the 3rd quarter. Fisher Asset Management LLC now owns 9,078,311 shares of the medical research company's stock valued at $599,078,000 after acquiring an additional 806,705 shares during the last quarter. Institutional investors own 79.46% of the company's stock.

Insider Buying and Selling

In other news, VP Donald E. Bobo, Jr. sold 5,000 shares of the company's stock in a transaction that occurred on Wednesday, November 13th. The stock was sold at an average price of $65.57, for a total transaction of $327,850.00. Following the completion of the transaction, the vice president now directly owns 46,936 shares of the company's stock, valued at $3,077,593.52. This represents a 9.63 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. Also, VP Daniel J. Lippis sold 500 shares of the stock in a transaction on Thursday, January 16th. The shares were sold at an average price of $68.76, for a total transaction of $34,380.00. Following the transaction, the vice president now directly owns 23,189 shares in the company, valued at approximately $1,594,475.64. The trade was a 2.11 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 33,000 shares of company stock valued at $2,195,180 over the last quarter. 1.27% of the stock is currently owned by company insiders.

Edwards Lifesciences Stock Down 0.1 %

EW stock traded down $0.09 during trading on Monday, reaching $69.77. 5,031,232 shares of the company traded hands, compared to its average volume of 4,364,863. The business has a 50 day simple moving average of $72.06 and a 200 day simple moving average of $71.18. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.89 and a current ratio of 3.46. Edwards Lifesciences Co. has a 12 month low of $58.93 and a 12 month high of $96.12. The company has a market capitalization of $41.15 billion, a price-to-earnings ratio of 10.07, a price-to-earnings-growth ratio of 3.77 and a beta of 1.11.

Edwards Lifesciences (NYSE:EW - Get Free Report) last issued its quarterly earnings results on Thursday, October 24th. The medical research company reported $0.67 earnings per share for the quarter, hitting analysts' consensus estimates of $0.67. Edwards Lifesciences had a return on equity of 20.76% and a net margin of 70.82%. The business had revenue of $1.35 billion for the quarter, compared to analyst estimates of $1.57 billion. During the same quarter in the previous year, the firm earned $0.59 earnings per share. The company's revenue was up 8.9% on a year-over-year basis. On average, equities research analysts anticipate that Edwards Lifesciences Co. will post 2.56 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts recently commented on the company. Truist Financial reaffirmed a "hold" rating and issued a $78.00 price objective (up previously from $70.00) on shares of Edwards Lifesciences in a report on Thursday, December 5th. Bank of America raised Edwards Lifesciences from a "neutral" rating to a "buy" rating and upped their price objective for the stock from $82.00 to $90.00 in a research note on Monday, December 16th. Royal Bank of Canada increased their price objective on shares of Edwards Lifesciences from $80.00 to $85.00 and gave the company an "outperform" rating in a report on Thursday, December 5th. Evercore ISI dropped their price objective on shares of Edwards Lifesciences from $76.00 to $70.00 and set an "in-line" rating for the company in a research note on Tuesday, October 1st. Finally, Wolfe Research downgraded Edwards Lifesciences from a "peer perform" rating to an "underperform" rating and set a $60.00 price target for the company. in a research report on Thursday. One equities research analyst has rated the stock with a sell rating, fifteen have assigned a hold rating and eleven have issued a buy rating to the company's stock. According to MarketBeat, the stock has a consensus rating of "Hold" and an average price target of $78.48.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.